In our own clinics we see people’s lives saved by bedaquiline.
Yet in 2018, only 1 in 5 people worldwide who could benefit were given access to bedaquiline.
We call on the drug corporation Johnson and Johnson (J&J) to recognise the joint research effort that went into the development of bedaquiline - a lifesaving TB drug developed with public funding and the contributions of the TB research community yet out of reach for many people living with TB.
But it is not up to J&J alone to set the price and control who gets access to bedaquiline and who does not.
J&J did not make this drug alone; they benefited from public and philanthropic funding, while the TB research community and treatment providers like MSF significantly contributed to the scientific evidence on bedaquiline’s therapeutic benefit.
Today we are demanding at J&J’s annual shareholder meeting that the company recognises the public’s right to a say in who can access this drug and to bring the price of bedaquiline down to a dollar a day.